The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis

Yajima, Takahiro; Yajima, Kumiko

doi:10.1016/j.jdiacomp.2018.05.018

Cited by 18 publications

(31 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, the effects of linagliptin on an animal model of premature aging supported a positive role in preventing muscle loss, based on the larger size of the gastrocnemius muscle in linagliptin‐treated mice compared with control . Teneligliptin, when compared with a GLP‐1R agonist, did not appear to have negative effects on skeletal muscle mass of patients with T2D on dialysis . However, with the recent increase in DPP‐4 inhibitor use, there have been reports of this class of medications causing myalgia, extremity pain, muscle weakness, and other musculoskeletal adverse events, such as arthralgia .…”

Section: Drugs and Musclementioning

confidence: 97%

“…Furthermore, in a clinical study, liraglutide was associated with an increase in the skeletal muscle index in overweight and obese patients with T2D . Despite these positive reported actions of GLP‐1R agonists on skeletal muscle, a very recent study from Japan evaluating changes in body composition of patients with T2D on hemodialysis showed decreases in skeletal muscle mass with 6 months of dulaglutide therapy, compared with teneligliptin therapy, raising some concern about dulaglutide‐induced muscle loss …”

Section: Drugs and Musclementioning

confidence: 99%

“…510 Despite these positive reported actions of GLP-1R agonists on skeletal muscle, a very recent study from Japan evaluating changes in body composition of patients with T2D on hemodialysis showed decreases in skeletal muscle mass with 6 months of dulaglutide therapy, compared with teneligliptin therapy, raising some concern about dulaglutide-induced muscle loss. 511 Sitagliptin has been shown to increase GLUT-4 expression in skeletal muscle of type 2 diabetic rats 512 and hypertensive rats. 513 MK-0626, a DPP-4 inhibitor, was associated with improvements in mitochondrial biogenesis in skeletal muscle and improvement in exercise capacity of mice who had suffered recent myocardial infarction.…”

Section: Incretinsmentioning

confidence: 99%

“…514 Teneligliptin, when compared with a GLP-1R agonist, did not appear to have negative effects on skeletal muscle mass of patients with T2D on dialysis. 511 However, with the recent increase in DPP-4 inhibitor use, there have been reports of this class of medications causing myalgia, extremity pain, muscle weakness, and other musculoskeletal adverse events, such as arthralgia. 284,285,515 Proposed mechanisms for these adverse events include a change in pain threshold or DPP4 inhibition in skeletal muscle.…”

Section: Incretinsmentioning

confidence: 99%

See 3 more Smart Citations

Diabetes pharmacotherapy and effects on the musculoskeletal system

Kalaitzoglou

Fowlkes

Popescu

et al. 2018

Diabetes Metabolism Res

View full text Add to dashboard Cite

Summary Persons with type 1 or type 2 diabetes have a significantly higher fracture risk than age‐matched persons without diabetes, attributed to disease‐specific deficits in the microarchitecture and material properties of bone tissue. Therefore, independent effects of diabetes drugs on skeletal integrity are vitally important. Studies of incretin‐based therapies have shown divergent effects of different agents on fracture risk, including detrimental, beneficial, and neutral effects. The sulfonylurea class of drugs, owing to its hypoglycemic potential, is thought to amplify the risk of fall‐related fractures, particularly in the elderly. Other agents such as the biguanides may, in fact, be osteo‐anabolic. In contrast, despite similarly expected anabolic properties of insulin, data suggests that insulin pharmacotherapy itself, particularly in type 2 diabetes, may be a risk factor for fracture, negatively associated with determinants of bone quality and bone strength. Finally, sodium‐dependent glucose co‐transporter 2 inhibitors have been associated with an increased risk of atypical fractures in select populations, and possibly with an increase in lower extremity amputation with specific SGLT2I drugs. The role of skeletal muscle, as a potential mediator and determinant of bone quality, is also a relevant area of exploration. Currently, data regarding the impact of glucose lowering medications on diabetes‐related muscle atrophy is more limited, although preclinical studies suggest that various hypoglycemic agents may have either aggravating (sulfonylureas, glinides) or repairing (thiazolidinediones, biguanides, incretins) effects on skeletal muscle atrophy, thereby influencing bone quality. Hence, the therapeutic efficacy of each hypoglycemic agent must also be evaluated in light of its impact, alone or in combination, on musculoskeletal health, when determining an individualized treatment approach. Moreover, the effect of newer medications (potentially seeking expanded clinical indication into the pediatric age range) on the growing skeleton is largely unknown. Herein, we review the available literature regarding effects of diabetes pharmacotherapy, by drug class and/or by clinical indication, on the musculoskeletal health of persons with diabetes.

show abstract

Section: Drugs and Musclementioning

confidence: 97%

Section: Drugs and Musclementioning

confidence: 99%

Section: Incretinsmentioning

confidence: 99%

Section: Incretinsmentioning

confidence: 99%

See 2 more Smart Citations

Diabetes pharmacotherapy and effects on the musculoskeletal system

Kalaitzoglou

Fowlkes

Popescu

et al. 2018

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…However, one study reported significant loss of fat mass and skeletal muscle mass in T2DM patients on hemodialysis after 6 months of dulaglutide treatment [55]. Although most studies of liraglutide have disclosed positive effects on muscle mass, it is currently unknown whether the effects of DPP4 inhibitors on sarcopenia are through a direct or indirect (i.e., through GLP-1 increase) mechanism.…”

Section: Sodium/glucose Cotransporter 2 Inhibitormentioning

confidence: 99%

The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review

Tien

2020

Journal of Diabetes Research

View full text Add to dashboard Cite

Sarcopenia is a geriatric syndrome characterized by decline of skeletal muscle mass and function. Contributing factors include nutritional, genetic, inflammatory, and endocrinal factors. The reported prevalence of sarcopenia in type 2 diabetes mellitus is high, especially in patients with poor glycemic control. Additionally, antidiabetic agents may alter the balance between protein synthesis and degradation through various mechanisms of skeletal muscle mass regulation. This study reviewed the literature on the pathogenesis of sarcopenia in diabetes mellitus and the current understanding of whether antidiabetic agents contribute positively or negatively to sarcopenia and muscle wasting.

show abstract

Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications

Zhang

Zhao

Chen

et al. 2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Sarcopenia, characterized by loss of skeletal muscle mass, quality, and strength, has become a common hallmark of ageing and many chronic diseases. Diabetes mellitus patients have a higher prevalence of sarcopenia, which greatly aggravates the metabolic disturbance and compromises treatment response. Preclinical and clinical studies have shown differential impacts of anti‐diabetic drugs on skeletal muscle mass, strength, and performance, highlighting the importance of rational therapeutic regimen from the perspective of sarcopenia risk. In this review, we provide an update on the regulation of muscle mass and quality by major anti‐diabetic drugs, focusing primarily on emerging data from clinical studies. We also discuss the underlying mechanisms and clinical implications for optimal selection of anti‐diabetic drugs to reduce the risk of sarcopenia. In view of the lifelong use of anti‐diabetic drugs, we propose that a better understanding of the sarcopenia risk and interventional strategies is worthy of attention in future studies.

show abstract

The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis

Cited by 18 publications

References 24 publications

Diabetes pharmacotherapy and effects on the musculoskeletal system

Diabetes pharmacotherapy and effects on the musculoskeletal system

The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review

Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications

Contact Info

Product

Resources

About